Discussion Group

Join the open finance hackers discussion group for updates and ideas here >>

(Freerisk is under active development, and not all the pieces are in place yet. This site is a work in progress and is here to inspire more people to get involved in the project)

What is Freerisk?

Freerisk is a project with the goal of making freely available the data, algorithms and tools necessary to perform risk modeling. We believe that risk management is too important to society to be an arcane subject or competitive advantage.

What are the pieces?

Who is involved?

Jesper Andersen

Jesper Andersen is the co-founder of Freerisk and is a statistician, computer scientist and entrepreneur.

He is currently a consultant with the Open Data Group, focusing on machine learning, risk assessment and artificial intelligence systems. He's spoken internationally on finance and statistical systems and is the founder of Certainty Labs, a startup focusing on making complex statistical modeling simpler. Previously he was the lead architect at Visible Path which was sold in 2008.

Jesper holds a B.Sc. in Physics from Haverford College and an M.B.A. from University of Chicago's Booth School of Business, where he received the “Most Promising Entrepreneur” award in 2008. He can be found wherever statistical uncertainty is a pressing issue.

Toby Segaran

Toby Segaran is the co-founder of Freerisk and is the author of the O’Reilly title, “Programming Collective Intelligence”, Amazon’s top-selling AI book. He frequently speaks on the subjects of machine learning, collective intelligence and freedom of data at conferences worldwide.

He currently holds the title of Data Magnate at Metaweb Technologies, where he works on large-scale data reconciliation problems. Prior to Metaweb he founded Incellico, a biotechnology software company, which was acquired in 2003.

Toby holds a B.Sc in Computer Science from MIT and is deemed a “Person of Exceptional Ability” by the USCIS. He loves applying data-analysis algorithms to everything ranging from pharmaceutical trials to online dating to financial risk models.